Zanubrutinib for treatment-naive and relapsed/refractory chronic lymphocytic leukaemia: long-term follow-up of the phase I/II AU-003 study was written by Cull, Gavin;Burger, Jan A.;Opat, Stephen;Gottlieb, David;Verner, Emma;Trotman, Judith;Marlton, Paula;Munoz, Javier;Johnston, Patrick;Simpson, David;Stern, Jennifer C.;Prathikanti, Radha;Wu, Kenneth;Novotny, William;Huang, Jane;Tam, Constantine S.. And the article was included in British Journal of Haematology in 2022.Product Details of 16506-27-7 The following contents are mentioned in the article:
Summary : The phase I/II AU-003 study in patients with treatment-naive (TN) or relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma demonstrated that zanubrutinib therapy results in clin. meaningful and durable responses with acceptable safety and tolerability. We report updated safety and efficacy data for 123 patients with a median follow-up of 47路2 mo. Patients received zanubrutinib 160 mg twice daily (81 patients), 320 mg once daily (40), or 160 mg once daily (two). Discontinuations due to adverse events or disease progression were uncommon. The overall response rate (ORR) was 95路9% (TN, 100%; R/R, 95%) with 18路7% achieving complete response (CR). Ongoing response at 3 years was reported in 85路7%. The ORR in patients with del(17p)/tumor protein p53 mutation was 87路5% (CR 16路7%). The 2- and 3-yr progression-free survival estimates were 90% (TN, 90%; R/R, 91%) and 83% (TN, 81%; R/R, 83%) resp. The most reported Grade 鈮? adverse events were neutropenia (15路4%), pneumonia (9路8%), hypertension (8路9%) and anemia (6路5%). The annual incidence of atrial fibrillation, major hemorrhage, Grade 鈮? neutropenia and Grade 鈮? infection decreased over time. With a median follow-up of 鈭? years, responses remain clin. meaningful and durable and long-term tolerability to zanubrutinib therapy continues. This study involved multiple reactions and reactants, such as 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7Product Details of 16506-27-7).
4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7) belongs to imidazole derivatives. Many natural products, especially alkaloids, contain the imidazole ring. These imidazoles share the 1,3-C3N2 ring but feature varied substituents. This ring system is present in important biological building blocks, such as histidine and the related hormone histamine.Product Details of 16506-27-7
Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem